-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
StockNews.com Upgrades Globus Medical (NYSE:GMED) to Buy
StockNews.com Upgrades Globus Medical (NYSE:GMED) to Buy
Globus Medical (NYSE:GMED – Get Rating) was upgraded by equities research analysts at StockNews.com from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Monday.
Other equities analysts have also recently issued reports about the stock. Wells Fargo & Company dropped their price objective on shares of Globus Medical from $80.00 to $70.00 in a research note on Wednesday, May 11th. Canaccord Genuity Group dropped their price objective on shares of Globus Medical from $80.00 to $75.00 in a research note on Wednesday, May 11th. BTIG Research dropped their price objective on shares of Globus Medical to $71.00 in a research note on Tuesday, August 9th. Piper Sandler dropped their price objective on shares of Globus Medical from $80.00 to $75.00 and set an "overweight" rating for the company in a research note on Friday, August 5th. Finally, Truist Financial dropped their price objective on shares of Globus Medical from $76.00 to $71.00 and set a "buy" rating for the company in a research note on Wednesday, July 20th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $77.36.
Get Globus Medical alerts:Globus Medical Stock Performance
Shares of NYSE GMED opened at $67.06 on Monday. The company has a market cap of $6.67 billion, a P/E ratio of 45.33, a P/E/G ratio of 3.19 and a beta of 1.13. The firm's fifty day moving average is $58.60 and its two-hundred day moving average is $65.38. Globus Medical has a 52-week low of $52.60 and a 52-week high of $84.23.
Institutional Investors Weigh In On Globus Medical
Large investors have recently added to or reduced their stakes in the stock. Tyler Stone Wealth Management purchased a new stake in Globus Medical in the 4th quarter valued at about $25,000. Signaturefd LLC boosted its position in Globus Medical by 93.8% in the 1st quarter. Signaturefd LLC now owns 345 shares of the medical device company's stock valued at $25,000 after buying an additional 167 shares during the period. Covestor Ltd purchased a new stake in Globus Medical in the 4th quarter valued at about $30,000. First Horizon Advisors Inc. boosted its position in Globus Medical by 3,325.0% in the 2nd quarter. First Horizon Advisors Inc. now owns 548 shares of the medical device company's stock valued at $30,000 after buying an additional 532 shares during the period. Finally, SeaCrest Wealth Management LLC purchased a new stake in Globus Medical in the 2nd quarter valued at about $31,000. 67.19% of the stock is owned by hedge funds and other institutional investors.About Globus Medical
(Get Rating)
Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.
See Also
- Get a free copy of the StockNews.com research report on Globus Medical (GMED)
- Are These 3 Video Game Stocks Now In Play?
- 2 Long-Term EV Plays Trading Under $20
- Why Apple is Primed to Take a Bite Out of Live Sports
- Exxon, Occidental Petroleum Lead Heavy Month Of Insider Buying
- Home Depot Results Point To Sluggish 2nd Half
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.
Globus Medical (NYSE:GMED – Get Rating) was upgraded by equities research analysts at StockNews.com from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Monday.
在周一发布给客户和投资者的一份研究报告中，股票研究分析师将Globus Medical(纽约证券交易所代码：GMED-GET Rating)的评级从持有上调至买入。
Other equities analysts have also recently issued reports about the stock. Wells Fargo & Company dropped their price objective on shares of Globus Medical from $80.00 to $70.00 in a research note on Wednesday, May 11th. Canaccord Genuity Group dropped their price objective on shares of Globus Medical from $80.00 to $75.00 in a research note on Wednesday, May 11th. BTIG Research dropped their price objective on shares of Globus Medical to $71.00 in a research note on Tuesday, August 9th. Piper Sandler dropped their price objective on shares of Globus Medical from $80.00 to $75.00 and set an "overweight" rating for the company in a research note on Friday, August 5th. Finally, Truist Financial dropped their price objective on shares of Globus Medical from $76.00 to $71.00 and set a "buy" rating for the company in a research note on Wednesday, July 20th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $77.36.
其他股票分析师最近也发布了有关该股的报告。富国银行在5月11日星期三的一份研究报告中将Globus Medical的股票目标价从80.00美元下调至70.00美元。在5月11日星期三的一份研究报告中，Canaccel Genuity Group将Globus Medical的股票目标价从80.00美元下调至75.00美元。BTIG Research在8月9日星期二的一份研究报告中将Globus Medical的股票目标价下调至71.00美元。8月5日，派珀·桑德勒在一份研究报告中将Globus Medical的股票目标价从80.00美元下调至75.00美元，并为该公司设定了“增持”评级。最后，Truist Financial在7月20日星期三的一份研究报告中将Globus Medical的股票目标价从76.00美元下调至71.00美元，并为该公司设定了“买入”评级。一名研究分析师对该股的评级为持有，九名分析师对该公司股票的评级为买入。根据MarketBeat的数据，该公司的共识评级为“适度买入”，共识目标价为77.36美元。
Globus Medical Stock Performance
Globus医疗类股表现
Shares of NYSE GMED opened at $67.06 on Monday. The company has a market cap of $6.67 billion, a P/E ratio of 45.33, a P/E/G ratio of 3.19 and a beta of 1.13. The firm's fifty day moving average is $58.60 and its two-hundred day moving average is $65.38. Globus Medical has a 52-week low of $52.60 and a 52-week high of $84.23.
周一，纽约证交所GMED的股价开盘报67.06美元。该公司市值为66.7亿美元，市盈率为45.33，市盈率为3.19，贝塔系数为1.13。该公司的50日移动均线切入位在58.60美元，200日移动均线切入位在65.38美元。Globus Medical的52周低点为52.60美元，52周高位为84.23美元。
Institutional Investors Weigh In On Globus Medical
机构投资者看好Globus Medical
About Globus Medical
关于Globus Medical
(Get Rating)
(获取评级)
Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.
Globus Medical，Inc.是一家医疗设备公司，为美国和国际上的肌肉骨骼疾病患者开发和销售保健解决方案。它提供脊柱产品，例如用于治疗退变、畸形、肿瘤和创伤条件的传统融合植入物，包括椎弓根螺钉和棒系统、钢板系统、椎间间隔器和椎体切除设备；运动保护技术的治疗选项，包括动态稳定、全椎间盘置换和棘间牵张设备；用于治疗椎体压缩骨折的介入性疼痛管理解决方案；以及由同种异体移植物和合成替代品组成的再生生物产品。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Globus Medical (GMED)
- Are These 3 Video Game Stocks Now In Play?
- 2 Long-Term EV Plays Trading Under $20
- Why Apple is Primed to Take a Bite Out of Live Sports
- Exxon, Occidental Petroleum Lead Heavy Month Of Insider Buying
- Home Depot Results Point To Sluggish 2nd Half
- 免费获取StockNews.com关于Globus Medical(GMED)的研究报告
- 这3只电子游戏股票现在还在玩吗？
- 2辆长期电动汽车的交易价格低于20美元
- 苹果为何准备退出体育直播
- 埃克森美孚和西方石油导致内幕人士本月大量买入
- 家得宝业绩指向低迷的下半年
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Globus医学日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Globus Medical和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧